A Phase 4 interventional study of Rivaroxaban 20 MG and Rivaroxaban 15 MG in Atrial Fibrillation and Anticoagulant Adverse Reaction, sponsored by Korea University Anam Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-01-05.
Sponsored by Korea University Anam Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing rivaroxaban in Atrial Fibrillation — 8 open to participants now, 9 under way, none of them phase 3. Rivaroxaban · Atrial Fibrillation.
Among the 45 studies testing rivaroxaban in Atrial Fibrillation, this one is the 16th largest by planned enrollment, is one of 4 that started in 2023, is one of 19 in phase 4, and was the 43rd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →8 of the 45 studies testing rivaroxaban in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 22+
China National Center for Cardiovascular Diseases · Sites in China
Ages 70+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–89
Xijing Hospital · Sites in China
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 19 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 17 · Phase 4 19
First in 2004; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 940 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 150 across the 45 interventional studies. Of the 26 that completed or were terminated, 7 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 45 have an industry lead sponsor. The 10 most frequent:
Korea University Anam Hospital is the lead sponsor of 114 studies on the registry; 33 are open to participants now.
Korea University Anam Hospital has 8 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
3 of the studies testing rivaroxaban in Atrial Fibrillation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06108414China National Center for Cardiovascular DiseasesLow-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation | 2026-12-31 |
| NCT05487950Assistance Publique - Hôpitaux de ParisRivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk | 2027-04-05 |
| NCT03129490Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation | 2027-10-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 45 studies testing rivaroxaban in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this clinical trial, Rivaroxaban of standard dose (20mg) and reduced dose (15mg) will be administeted in non-valvular atrial fibrillation patients without severe renal dysfunction.
It is a randomized, open-label, and phase 4 clinical trial to compare and evaluate efficacy and safety of Rivaroxaban.
After obtaining informed consent to participate in this trial, screening is performed (Screening visit).
Screening includes baseline 12-lead electrocardiography and laboratory tests to exclude severe end-organ dysfunction (such as renal dysfunction, liver dysfunction, or anemia).
Baseline visits are available on the same day. After screening, subjects eligible for the trial will be randomly assigned (1:1 ratio) to Group 1 (15 mg of Rivaroxaban) or Group 2 (20 mg of Rivaroxaban) (Baseline visit).
The study drug (Rivaroxaban 15mg or 20mg daily) will be administered for 12 months.
During study period, a total of six visits (3,6,9,12 months) will be made, and follow-up test and outcome measurement will be done in each visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with increased risk of bleeding due to the following conditions:
Gastrointestinal ulcer history within 6 months prior to random allocation
Intracranial or intracranial hemorrhage history within 6 months prior to random assignment
vascular abnormalities in the spinal cord or brain
History of brain, spinal cord or ophthalmic surgery within 30 days prior to random assignment
⑤ Brain or spinal cord injury within 6 months prior to random allocation
⑥ If you have esophageal varices or are suspected
⑦ Arteriovenous malformations
⑧ Vascular aneurysms
⑨ Patients with malignant tumors (Neoplasm) at high risk of bleeding
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects eligible for this clinical trial will be randomly assigned to Group 1 (15 mg of rivaroxaban) or Group 2 (20 mg of rivaroxaban) at baseline visits in a 1:1 ratio.
Drug: Rivaroxaban 15 MG
Subjects eligible for this clinical trial will be randomly assigned to Group 1 (15 mg of rivaroxaban) or Group 2 (20 mg of rivaroxaban) at baseline visits in a 1:1 ratio.
Drug: Rivaroxaban 20 MG
Subjects should take clinical trial drugs (20 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
Subjects should take clinical trial drugs (15 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
Incident rate of major bleeding events
Incidence of 'major bleeding' defined by International Society on Thrombosis and Haemostasis (ISTH) : (i) hb decrease 2 g/dL or more, or (ii) bleeding requiring RBC transfusion 2 or more unites, (iii) bleeding at major organ (intracranial, intraocular, pericardial, intra-articular, retroperitoneal or intramuscular bleeding), (iv) bleeding that result lethal outcome
Time frame: At baseline(Visit 2) and at 3 month, 6 month, 9 month, 12 month after the baseline visit, or at 1~3 month interval with regard to the subject's therapy.
Occurrence of Stroke, Non-CNS systemic embolism, and vascular death death
Composite of stroke, Non-CNS systemic embolism, and vascular death death
Time frame: At baseline(Visit 2) and at 3 month, 6 month, 9 month, 12 month after the baseline visit, or at 1~3 month interval with regard to the subject's therapy.
Occurrence of Stroke, Non-CNS systematic embolism, and myocardial infarction infaration, cardiovascular death
Composite of stroke, Non-CNS systemic embolism, and myocardial infarction
Time frame: At baseline(Visit 2) and at 3 month, 6 month, 9 month, 12 month after the baseline visit, or at 1~3 month interval with regard to the subject's therapy.
Occurrence Stroke, Non-CNS systemic embolism, myocardial infarction (Myocardial infarction), (Cardio vascular death)
Individual incidence of stroke, Non-CNS systemic embolism, and myocardial infarction
Time frame: At baseline(Visit 2) and at 3 month, 6 month, 9 month, 12 month after the baseline visit, or at 1~3 month interval with regard to the subject's therapy
Occurrence of Severe Disabling Stroke
Severe stroke that results Modified Rankin Scale between 3 \~ 5
Time frame: At baseline(Visit 2) and at 3 month, 6 month, 9 month, 12 month after the baseline visit, or at 1~3 month interval with regard to the subject's therapy.
All-cause motality
Death of any cuase
Time frame: At baseline(Visit 2) and at 3 month, 6 month, 9 month, 12 month after the baseline visit, or at 1~3 month interval with regard to the subject's therapy.
Incidence of non-major clinically significant bleeding*
Any bleeding that do not fulfill 'major bleeding', but requring clinical intervention or unexpected medical visit, cease of study
Time frame: At baseline(Visit 2) and at 3 month, 6 month, 9 month, 12 month after the baseline visit, or at 1~3 month interval with regard to the subject's therapy
Abnormal reaction and drug abnormal reaction expression, vital sign, laboratory inspection, physical examination, 12-lead ECG
Time frame: At baseline(Visit 2) and at 3 month, 6 month, 9 month, 12 month after the baseline visit, or at 1~3 month interval with regard to the subject's therapy
Number of unexpected medical service visit (Healthcare Utilization)
Any visit of medical service except routine visits
Time frame: At baseline(Visit 2) and at 3 month, 6 month, 9 month, 12 month after the baseline visit, or at 1~3 month interval with regard to the subject's therapy.
Proportion of the drug taken during study period (Treatment persistence)
Maintenance of treatment to drug administration and treatment adherence
Time frame: At baseline(Visit 2) and at 3 month, 6 month, 9 month, 12 month after the baseline visit, or at 1~3 month interval with regard to the subject's therapy.
Plan to share: No
Started Jan 2023 (actual). Primary completion is estimated for Jun 2026, 41 months after the start.
Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 41 months is below that.
Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban
Korea University Anam Hospital →